1

Discovery

2

Optimization

3

Preclinical

4

Phase 1

Allogeneic format
Invariant natural killer T cells (iNKT)
Native iNKT
IND 2019 (Projected)
Undisclosed CAR
NY-ESO-1 TCR
Undisclosed TCR
Undisclosed TCR
Undisclosed CAR
Novel Targets
Phosphopeptide Tumor Targets(PTTs)
MLL TCR
PTT TCRs
(multiple)